Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Region, And Segment Forecasts, 2019 - 2026

Published: Sep, 2019 | Pages: 105 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

The global breast cancer diagnostics market is expected to reach USD 8.4 billion by 2026, expanding at a 7.7.% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Factors such as growing incidence of breast cancer and increasing healthcare spending and research activities are projected to drive the growth.

Breast cancer is the leading cause of cancer-related death among women and is the most common type of cancer overall. As per the World Cancer Research Fund (WCRF) International, around 2 million new breast cancer cases were recorded globally in 2018. According to Breastcancer.org, in U.S., around one in every women will be diagnosed with invasive breast cancer during her lifetime. It is projected that around 268,600 new cases of invasive breast cancer will be detected in U.S., in 2019.

Healthcare organizations and governments are striving to raise awareness regarding early diagnosis of the disease, through various independent and collaborative initiatives. Furthermore, research entities, along with private and public organizations, are heavily investing in research projects to develop advanced breast cancer diagnostics, which can diagnose the disease even before the symptoms appear.

Based on type, the imaging segment accounted for the largest share of the breast cancer diagnostics market in 2018 due to the increasing prevalence of the disease. Availability of various imaging methods such as breast MRI, ultrasonography, diagnostic mammography, and screening mammography is anticipated to bode well for the growth. These tests enable quick and accurate diagnosis. In addition, owing to the new technologically advanced techniques such as contrast-enhanced digital mammography, the segment is expected to maintain its dominance over the forecast period. The new techniques can detect the disease a little earlier by revealing growth of the blood vessels related to the tumor.

Further key findings from the report suggest:

• The blood test is expected to be the fastest growing segment over the forecast period owing to the launch of new blood tests. For instance, The Heidelberg University Hospital in Germany introduced a test that can detect breast tumor quickly and noninvasively using biomarkers in the blood

• North America was the largest revenue generating region in 2018 followed by Europe. High R&D activities, well-established diagnostic infrastructure, patient awareness, and presence of key players are some of the factor attributed to their continued dominance

• Asia Pacific is expected to witness the fastest CAGR during the forecast period owing to the presence of large population base, target population, and high unmet clinical needs

• Few major players operating in the breast cancer diagnostics market are Myriad Genetics, Inc.; Genomic Health; Hologic Inc.; NanoString Technologies, Inc.; Danaher; Koninklijke Philips N.V.; Becton, Dickinson and Company; Devicor Medical Products Inc.; and C.R. Bard, Inc.

• The key players are adopting different strategies such as product development, collaborations, and geographic expansion to increase their market share.

 Table of Contents

Chapter 1. Methodology and Scope
                     1.1.Market Segmentation & Scope
                     1.2. Market Definition
                     1.3. Information Procurement
                          1.3.1. Purchased database
                          1.3.2. GVR's internal database
                          1.3.3. Secondary sources & Third party perspectives
                          1.3.4. Primary research
                     1.4. Information Analysis
                          1.4.1. Data analysis models
                     1.5. Market Formulation & Data Visualization
                     1.6. Data Validation & Publishing
Chapter 2. Executive Summary
                     2.1. Market Outlook
                     2.2. Segment Outlook
                     2.3. Competitive Insights
Chapter 3. Breast Cancer Diagnostics Market Variables, Trends & Scope
                     3.1. Market Lineage Outlook
                          3.1.1. Parent Market Outlook
                     3.2. Penetration & Growth Prospect Mapping
                     3.3. Regulatory Framework
                          3.3.1. Reimbursement framework
                     3.4. Market Dynamics
                          3.4.1. Market driver analysis
                               3.4.1.1. Increasing incidence of breast cancer
                               3.4.1.2. Favourable reimbursement framework for breast cancer diagnosis
                               3.4.1.3. Growing number of breast cancer screening programs
                     3.5. Market restraint analysis
                          3.5.1. Regulatory issues
                     3.6. Breast Cancer Diagnostics Market Analysis Tools
                          3.6.1. Industry analysis - Porter's
                               3.6.1.1. Supplier power (Moderate due to requirement of high-quality raw materials)
                               3.6.1.2. Buyer power (Moderate due to limited number of established providers)
                               3.6.1.3. Substitution threat (Moderate due to high costs of instruments)
                               3.6.1.4. New entrants' threat (Low due to huge capital investment)
                               3.6.1.5. Competitive rivalry (Moderate due to presence of few key players)
                     3.7. PESTEL analysis
                          3.7.1. Political landscape
                          3.7.2. Environmental landscape
                          3.7.3. Social landscape
                          3.7.4. Technology landscape
                          3.7.5. Legal landscape
Chapter 4. Breast Cancer Diagnostics Market - Competitive Analysis
                     4.1. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
                     4.2. Public Companies
                          4.2.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
                          4.2.2. Company market share
                     4.3. Private Companies
                          4.3.1. List of key emerging companies
                          4.3.2. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Breast Cancer Diagnostics Market: Type Estimates & Trend Analysis
                     5.1. Definitions & Scope
                     5.2. Type Market Share Analysis, 2018 & 2026
                     5.3. Breast Cancer Diagnostics Market, by Type, 2015 to 2026
                     5.4. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
                          5.4.1. Imaging
                               5.4.1.1 Imaging market, 2015 - 2026 (USD Million)
                          5.4.2. Biopsy
                               5.4.2.1 Biopsy market, 2015 - 2026 (USD Million)
                          5.4.3. Genomic Tests
                               5.4.3.1 Genomic tests market, 2015 - 2026 (USD Million)
                          5.4.4. Blood Tests
                               5.4.4.1 Blood tests market, 2015 - 2026 (USD Million)
                          5.4.5. Others
                               5.4.5.1 Others market, 2015 - 2026 (USD Million)
Chapter 6 Breast Cancer Diagnostics Market: Regional Estimates & Trend Analysis, by Drug
                     6.1 Breast Cancer Diagnostics Market: Regional Movement Analysis, 2018 & 2026
                     6.2 Breast Cancer Diagnostics Market: Leading Players, 2018:
                          6.2.1. North America
                          6.2.2. Europe
                          6.2.3. Asia Pacific
                          6.2.4. Latin America
                          6.2.5. MEA
                     6.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
                          6.3.1. North America
                          6.3.2. Europe
                          6.3.3. Asia Pacific
                          6.3.4. Latin America
                          6.3.5. MEA
                     6.4 North America
                          6.4.1 North America market, 2015 - 2026 (USD Million)
                          6.4.2 U.S.
                               6.4.2.1 U.S. market, 2015 - 2026 (USD Million)
                          6.4.3 Canada
                               6.4.3.1 Canada market, 2015 - 2026 (USD Million)
                     6.5. Europe
                          6.5.1 Europe market, 2015 - 2026 (USD Million)
                          6.5.2 U.K.
                               6.5.2.1 U.K. market, 2015 - 2026 (USD Million)
                          6.5.3 Germany
                               6.5.3.1 Germany market, 2015 - 2026 (USD Million)
                          6.5.4 France
                               6.5.4.1 France market, 2015 - 2026 (USD Million)
                          6.5.5 Italy
                               6.5.5.1 Italy market, 2015 - 2026 (USD Million)
                          6.5.6 Spain
                               6.5.6.1 Spain market, 2015 - 2026 (USD Million)
                     6.6 Asia Pacific
                          6.6.1 Asia Pacific market, 2015 - 2026 (USD Million)
                          6.6.2 Japan
                               6.6.2.1 Japan market, 2015 - 2026 (USD Million)
                          6.6.3 China
                               6.6.3.1 China market, 2015 - 2026 (USD Million)
                          6.6.4 India
                               6.6.4.1 India market, 2015 - 2026 (USD Million)
                          6.6.5 South Korea
                               6.6.5.1 South Korea market, 2015 - 2026 (USD Million)
                          6.6.6 Australia
                               6.6.6.1 Australia market, 2015 - 2026 (USD Million)
                     6.7 Latin America
                          6.7.1 Latin America market, 2015 - 2026 (USD Million)
                          6.7.2 Brazil
                               6.7.2.1 Brazil market, 2015 - 2026 (USD Million)
                          6.7.3 Mexico
                               9.7.3.1 Mexico market, 2015 - 2026 (USD Million)
                          9.7.4 Colombia
                               6.7.4.1 Colombia market, 2015 - 2026 (USD Million)
                          6.7.5 Chile
                               6.7.5.1 Chile market, 2015 - 2026 (USD Million)
                          6.7.6 Argentina
                               6.7.6.1 Argentina market, 2015 - 2026 (USD Million)
                     6.8 MEA
                          6.8.1 MEA market, 2015 - 2026 (USD Million)
                          6.8.2 South Africa
                               6.8.2.1 South Africa market, 2015 - 2026 (USD Million)
                          6.8.3 Saudi Arabia
                               6.8.3.1 Saudi Arabia market, 2015 - 2026 (USD Million)
                          6.8.4 UAE
                               6.8.4.1 UAE market, 2015 - 2026 (USD Million)
Chapter 7 Competitive Landscape
                     7.1 Strategy Framework
                     7.2 Heat Map Analysis of Private Companies
                          7.2.1 Company size
                          7.2.2 Distribution network
                          7.2.3 Product portfolio
                          7.2.4 Segment coverage
                          7.2.5 Geographic presence
                          7.2.6 Collaborations
                          7.2.7 Conclusion
                     7.3 Genomic Health
                          7.3.1 Company overview
                          7.3.2 Financial performance
                          7.3.3 Product benchmarking
                          7.3.4 Strategic initiatives
                     7.4 Myriad Genetics, Inc.
                          7.4.1 Company overview
                          7.4.2 Financial performance
                          7.4.3 Product benchmarking
                          7.4.4 Strategic initiatives
                     7.5 NanoString Technologies, Inc.
                          7.5.1 Company overview
                          7.5.2 Financial performance
                          7.5.3 Product benchmarking
                          7.5.4 Strategic initiatives
                     7.6 Hologic Inc
                          7.6.1 Company overview
                          7.6.2 Financial performance
                          7.6.3 Product benchmarking
                          7.6.4 Strategic initiatives
                     7.7 Koninklijke Philips N.V.,
                          7.7.1 Company overview
                          7.7.2 Financial performance
                          7.7.3 Product benchmarking
                          7.7.4 Strategic initiatives
                     7.8 Danaher
                          7.8.1 Company overview
                          7.8.2 Financial performance
                          7.8.3 Product benchmarking
                          7.8.4 Strategic initiatives
                     7.9 Becton, Dickinson and Company
                          7.9.1 Company overview
                          7.9.2 Financial performance
                          7.9.3 Product benchmarking
                          7.9.4 Strategic initiatives
                     7.10 C.R. Bard, Inc.
                          7.10.1 Company overview
                          7.10.2 Financial performance
                          7.10.3 Product benchmarking
                          7.10.4 Strategic initiatives
                     7.11 Devicor Medical Products Inc.
                          7.11.1 Company overview
                          7.11.2 Financial performance
                          7.11.3 Product benchmarking
                          7.11.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 3 U.S. breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 4 Canada breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 5 Europe breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 6 U.K. breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 7 Germany breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 8 France breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 9 Spain breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 10 Italy breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 11 Asia Pacific breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 12 Japan breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 13 China breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 14 India breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 15 South Korea breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 16 Australia breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 17 Latin America breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 18 Brazil breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 19 Mexico breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 20 Colombia breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 21 Chile breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 22 Argentina breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 23 Middle East & Africa breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 24 South Africa breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 25 Saudi Arabia breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 26 UAE breast cancer diagnostics market estimates and forecasts, by type, 2015 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary, 2018
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 Market restrain relevance analysis (Current & future impact)
FIG. 8 Penetration & growth prospect mapping
FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 10 Porter's five forces analysis
FIG. 11 Breast cancer diagnostics market type outlook key takeaways
FIG. 12 Breast cancer diagnostics market: Type movement analysis
FIG. 13 Imaging market, 2015 - 2026 (USD Million)
FIG. 14 Biopsy market, 2015 - 2026 (USD Million)
FIG. 15 Genomic tests market, 2015 - 2026 (USD Million)
FIG. 16 Blood tests market, 2015 - 2026 (USD Million)
FIG. 17 Others market, 2015 - 2026 (USD Million)
FIG. 18 Regional market place: Key takeaways, 2018
FIG. 19 Regional outlook, 2018 & 2026
FIG. 20 North America breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 21 U.S. breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 22 Canada breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 23 Europe breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 24 U.K. breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 25 Germany breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 26 France breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 27 Spain breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 28 Italy breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 29 Asia Pacific breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 30 Japan breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 31 China breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 32 India breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 33 South Korea breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 34 Australia breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 35 Latin America breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 36 Brazil breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 37 Mexico breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 38 Colombia breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 39 Chile breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 40 Argentina breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 41 Middle East & Africa breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 42 South Africa breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 43 Saudi Arabia breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 44 UAE breast cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 45 Strategy framework
FIG. 46 Participant categorization